地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:18995651644
邮箱:sales@amyjet.com

艾美捷科技代理Seven Hills Bioreagents品牌。
Seven Hills Bioreagents是一家专注于为生物医学研究和诊断领域提供高质量生物试剂的公司,用户涵盖全球的学术研究机构、生物技术公司、制药公司和诊断实验室。包括包括单克隆抗体、多克隆抗体、重组蛋白、ELISA试剂盒、免疫组化试剂等,广泛应用于癌症研究、免疫学、神经科学、传染病研究等领域。Seven Hills Bioreagents公司凭借其高质量的产品和优质的服务,严格遵循ISO 9001等国际标准,确保产品和服务的高质量,已成为生物医学研究和诊断领域的重要供应商,持续为全球科研和诊断行业提供关键支持。
<<< " data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Seven Hills Bioreagents品牌"> 艾美捷科技代理Seven Hills Bioreagents品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

ScyTek始创于1991年,以成为世界级生命科学研究试剂生产商为目标。ScyTek从创立之初开始, 就采取了严格的原材料筛选程序,确保所有出厂产品都具有最高的品质。按照为工业客户提供OEM服务以及同时服务科研市场的策略,ScyTek能够进行大批量生产而保持总成本降到最低,始终坚持为客户传递其成本优势的政策。如今,ScyTek生产多种优质试剂,不断应用于各种学科,包括免疫学,组织学,细胞学,微生物学和血液学等。
ScyTek Laboratories was founded in 1991 with the goal of becoming a world class manufacturing company producing reagents for the life sciences market. ScyTek selected Utah due to its position as a central hub for the western United States. Among its many advantages, Utah has a highly educated workforce combined with a relatively low cost geographical region.
ScyTek公司产品主要有:
Enzyme Immunoassay
Immunohistochemistry
Antibodies
DNA Ploidy Analysis
Histology
Cytology
Hematology
Microbiology
Buffers
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ScyTek"> ScyTek
艾乐美生物科技有限公司(AllerMAbs Co., Ltd.)成立于2015年,是台湾一家专注于生产高亲和力、高纯度并具有过敏原特异性的嵌合人类IgE单克隆抗体的生物公司。公司创办人团队在科研过程中发现市面上缺乏多样的IgE单克隆抗体,特別是具有过敏原特异性的人IgE 单抗。如果能制备出这种抗体,将有助于IgE 相关领域的研究工作。因此,AllerMAbs公司团队开始思考与研究利用基因克隆动物来制造人类 IgE 抗体的可行性,经过数年的努力于 2014年开发出人类IgE 抗体基因嵌入小鼠,通过杂交瘤技术 (Hybridoma technology),成功地研制出分泌嵌合人类IgE 单抗的 IgE 杂交瘤与纯化 IgE 抗体。经测试,此种嵌合人类IgE 单抗的物化性质与对免疫细胞的活性,皆与人类IgE 抗体一致,研究成果于2015 年发表在国际学术期刊上。
AllerMAbs的产品解决了目前人类IgE抗体不易制备的问题,让嵌合人类IgE抗体可以成为人类IgE抗体的替代品,并提供一个更稳定、更符合血清IgE检测系统的校正品,让临床血清IgE的检测结果更加准确与可靠。
其利用动物基因转殖技术,将组成人类IgE抗体分子的ε重链(Heavy chain)和κ轻链(Light chain)的编码基因(Encoding genes),分別嵌入(Knock-in)小鼠胚胎干细胞(Embryonic stem cells, ES cells)的γ1重链和κ轻链基因的位置,接着把胚胎干细胞分別植入孕母鼠体内,并将其带有嵌入基因之成鼠交互配种,最后得到带有人类IgE抗体重链和轻链基因的基因嵌入小鼠(HεκKI mice),且体内能制造完整的嵌合人类IgE抗体分子。
技术优势
容易制备IgE杂交瘤与IgE单抗
过敏原特异性
良好的亲和力与专一性
高纯度与高稳定性
可结合至嗜碱性粒细胞上的IgE受体与刺激細胞
可大量生产与高浓度制备
非人类血液来源(相较于血清IgE抗体)
适合用作检测用的校正品
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="AllerMAbs"> AllerMAbs
eENZYME为科学界生产和销售高质量的生物试剂盒和生物分析试剂盒。与NIH密切合作以保证产品在生命科学研究的多个领域成功地使用。努力提供新颖价廉且有效的工具,使实验更容易成功。产品在科研、生物技术、制药和政府的研究实验室中得到广泛的应用,包括药物发现、癌症研究、传染病研究、微生物学和分子诊断。
eENZYME is a manufacturer and distributor of high quality biological reagents and bio-assay kits to the scientific community. We work closely with the NIH and CDC communities to guarantee the successful performance of our products for life science research in broad areas. We strive to provide innovative and cost effective tools to make your success easier.
Our products are used in academic, biotechnology, pharmaceutical and government research laboratories in many diverse applications that include drug discovery, cancer research, infectious disease research, microbiology and molecular diagnostics.
eEnzyme公司的主要产品包括:
Frontline Infectious Disease Products
Infectious Disease Antibodies & ELISA Kits
Recombinant Viral & Bacterial Proteins
Virus ORF cDNA Clone
Influenza Virus Research
HIV Research Tools
GPCR/PDE Cell-Based HTS Assays
Cell Assay & Molecule Detection Kits
PCR Tools
Mol. & Cell Biology Reagents
Animal-Free Human Proteins
Antibody & Protein Production
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="eEnzyme"> eEnzyme

艾美捷科技代理Biotium品牌全系列染料产品。
Biotium一直致力于开发和生产用于生物医学研究的荧光指示剂及其他特殊生化产品。其产品被广泛应用于细胞生 物学、蛋白质组学、分子生物学、免疫学、微生物学、诊断学、生物化学、神经科学、血液流动检测及大规模药物筛选等众多领域。产品列表如下:
| 产品名称 | 货号 | 规格 | |
| GelRed® Nucleic Acid Gel Stain 10000X in water, 0.5ml | 41003 | 0.5ml | |
| GelRed® Nucleic Acid Gel Stain 10000X in water, 10ml | 41003-1 | 10ml | |
| GelRed® Nucleic Acid Gel Stain 3X in water, 4L | 41001 | 4L | |
| GelRed® Nucleic Acid Gel Stain 10000X in DMSO, 0.5ml | 41002 | 0.5ml | |
| GelRed® Nucleic Acid Gel Stain 10000X in DMSO, 10ml | 41002-1 | 10ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in water, 0.5ml | 41005 | 0.5ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in water, 10ml | 41005-1 | 10ml | |
| GelGreen® Nucleic Acid Gel Stain 10000X in DMSO, 0.5ml | 41004 | 0.5ml | |
| GelRed® Agarose LE, 5g | 41029-5G | 5g | |
| GelRed® Agarose LE, 50g | 41029-50G | 50g | |
| GelGreen® Agarose LE, 5g | 41030-5G | 5g | |
| GelGreen® Agarose LE, 50g | 41030-50G | 50g | |
| 6X GelRed® Prestain Loading Buffer with Orange Tracking Dye | 41010 | 1ml | |
| PAGE GelRed® Nucleic Acid Gel Stain 10000X in water, 0.1ml | 41008-T | 0.1ml | |
| PAGE GelRed® Nucleic Acid Gel Stain 10000X in water, 500uL | 41008-500uL | 500ul | |
| PAGE GelRed® Nucleic Acid Gel Stain 1X in water, 4L | 41014 | 4L | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 25 uL | 40061-T | 25ul | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 250 uL | 40061 | 250ul | |
| RedDot™2 Far-Red Nuclear Stain, 200X in DMSO, 1 mL | 40061-1 | 1ml | |
| EvaGreen® Dye, 20X in Water, 1mL | 31000-T | 1ml | |
| EvaGreen® Dye, 20X in Water, 5 x 1 mL | 31000 | 5x1ml | |
| AO Succinimidyl Ester | 40074 | 5mg | |
| DMAO, 2 mM in DMSO | 40012 | 1ml | |
| EB Succinimidyl Ester | 40072 | 5mg | |
| Ethidium Homodimer III (EthD-III) | 40050 | 1mg | |
| Ethidium Homodimer III (EthD-III), 1 mM in DMSO | 40051 | 200ul | |
| EvaGreen® Dye, 2000X in DMSO | 31019 | 50ul | |
| MB Acid | 40076 | 5mg | |
| MB Succinimidyl Ester | 40075 | 5mg | |
| Thiazole Green (SYBR® Green I), 10,000X in DMSO, 0.5 mL | 40086-0.5mL | 0.5ml | |
| Thiazole Green (SYBR® Green I), 10,000X in DMSO, 1mL | 40086-1mL | 1ml | |
| Thiazole Orange Homodimer (TOTO®-1), 1 mM in DMSO | 40079 | 200ul | |
| Thiazole Orange, 10 mM in DMSO | 40077 | 1mL | |
| Thiazole Red (TO-PRO®-3), 1 mM in DMSO | 40087 | 1mL | |
| Thiazole Red Homodimer (TOTO®-3), 1 mM in DMSO | 40080 | 200ul | |
| TO Succinimidyl Ester | 40073 | 5mg | |
| DAPI, 10 mg | 40011 | 10mg | |
| DAPI, 10 mg (Dilactate) | 40009 | 10mg | |
| DAPI, 1 mL (10 mg/mL) | 40043 | 1ml | |
| Ethidium Homodimer I (EthD-I), 1 mg | 40010 | 1mg | |
| Ethidium Homodimer I (EthD-I), 0.5 mL (2 mM in DMSO) | 40014 | 0.5ml | |
| GelRed® Prestain Plus 6X DNA Loading Dye | 41011 | 1ml | |
| 7-AAD, 1mg | 40037 | 1mg | |
| 7-AAD, 1 mL (1 mg/mL) | 40084 | 1ml | |
| Acridine Orange, 10 mg/mL in Water (High Purity) (AO) | 40039 | 10ml | |
| Actinomycin D | 40038 | 10mg | |
| DiSC2(5) (High Purity) | 40041 | 50mg | |
| DODC (High Purity) | 40040 | 50mg | |
| Ethidium Bromide, 10 mg/mL in H2O | 40042 | 10ml | |
| Hoechst 33258, 10 mL (10 mg/mL) | 40044 | 10ml | |
| Hoechst 33258, 100mg | 40045 | 100mg | |
| Hoechst 33342, 10 mL (10 mg/mL) | 40046 | 10ml | |
| Hoechst 33342, 100mg | 40047 | 100mg | |
| PMAxx™ Dye, 20 mM in H2O | 40069 | 100ul | |
| Propidium Iodide (PI), 10 mL (1 mg/mL in Water) | 40017 | 10ml | |
| Propidium Iodide (PI), 2 mL (50 ug/mL in Buffer) | 40048 | 2ml | |
| Propidium Iodide (PI), 100 mg | 40016 | 100mg | |
| PMA (Propidium Monoazide), 100uL | 40019 | 100ul | |
| PMA (Propidium Monoazide), 1mg | 40013 | 1mg | |
| Ethidium Monoazide Bromide (EMA) | 40015 | 1mg |

艾美捷科技特约代理F.S.T(Fine Science Tools)公司全系列产品。
F.S.T(Fine Science Tools)公司以追求高质量的产品和优质的服务为目标,为医护和科研人员提供医疗和动物精密手术器械,因而成为全球领先的手术器械生产商和供应商。F. S. T拥有手术剪、手术镊、骨科器械、手术刀及刀片、血管钳、持针钳等10余类共1000余种。
Fine Science Tools is the leading distributor of precision European surgical and microsurgical instruments to the scientific and biomedical research community.
Fine Science Tools公司的主要产品包括:
Scissors
Bone Instruments
Scalpels & Blades
Curettes, Spatulae & Probes
Pins
Wound Closure
Retractors
Vascular Instruments
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Fine Science Tools"> Fine Science Tools
Mirus Bio公司是世界上最早开发高效、低细胞毒性转染试剂的公司之一,同时也是目前该类试剂最主要的供应商之一。Mirus Bio的大部分转染试剂可以在含有血清的培养基中进行转染,省去了更换培养基的麻烦。TransIT-L1是Mirus产品的王牌,自1995年开发出来就申请了美国专利(US 5,744,335)。该项专利技术后来License给了Roche公司,以Fugene 6的品牌对外销售。TransIT-TKO & siQUEST转染试剂是常规siRNA转染试剂的王牌,与脂质体介导的转染试剂相比,该转染试剂可以高效转染siRNA,并且极大地降低了细胞的损伤程度。该试剂与siRNA混合转染细胞时,可以特异性剔除某些基因的表达,用于siRNA介导的基因沉默现象的研究。TransIT-Oligo转染试剂是即用型试剂,可以高效地将各种类型的寡聚核苷酸和寡聚脱氧核苷酸转染至受体细胞中。
此外,Mirus Bio还开发了专门针对特殊细胞的体外转染试剂,例如分别针对Jurkat,COS,3T3等细胞的转染试剂。Mirus Bio的科学家们新近开发了一种新的DNA转染试剂:TransITTM-2020 Transfection Reagent。TransITTM的性能优于FuGENETM、LipofectamineTM 2000和 LipofectamineTM 2000 CD;可在多种类型的细胞(包括难转染细胞)中实现高表达。
Mirus was founded on the principle that non-viral (i.e. plasmid DNA based) methods offer distinct advantages over viral methods of gene transfer. Our initial breakthrough in 1996 came with the development of a new type of transfection reagent that combined high efficiency delivery with low cellular toxicity: TransIT®-LT1 (Low Toxicity) Reagent remains the “gold standard” for broad-based gene delivery applications.
Mirus Bio公司主要产品:
Transfection with TransIT
Ingenio® Electroporation
Virus Production
Labeling with Label IT®
In Vivo Delivery
Accessory Products
| 品名 | 货号 |
| Human IgG1 Expression Control – 100 ug | MIR 6250 |
| Ingenio EZporator Electroporation System | MIR 51000 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 25 µg of nucleic acid | MIR 3925 |
| Label IT Nucleic Acid Labeling Kit, Amine – sufficient for modifying 100 µg of nucleic acid | MIR 3900 |
| TransIT-2020 Transfection Reagent – 0.4 mL | MIR 5404 |
| TransIT-2020 Transfection Reagent – 1.0 mL | MIR 5400 |
| TransIT-2020 Transfection Reagent – 10 X 1.0 mL | MIR 5406 |
| TransIT-2020 Transfection Reagent – 5 X 1.0 mL | MIR 5405 |
| TransIT-293 Transfection Reagent – 0.4 mL | MIR 2704 |
| TransIT-293 Transfection Reagent – 1.0 mL | MIR 2700 |
| TransIT-293 Transfection Reagent – 10 X 1.0 mL | MIR 2706 |
| TransIT-293 Transfection Reagent – 5 X 1.0 mL | MIR 2705 |
| TransIT-CHO Transfection Kit – 10 X 1.0 mL | MIR 2176 |
| TransIT-CHO Transfection Kit – 5 X 1.0 mL | MIR 2175 |
| TransIT-CHO Transfection Kit – 1.0 mL | MIR 2170 |
| TransIT-HeLaMONSTER Transfection Kit – 0.4 mL | MIR 2904 |
| TransIT-HeLaMONSTER Transfection Kit – 1.0 mL | MIR 2900 |
| TransIT-HeLaMONSTER Transfection Kit – 10 X 1.0 mL | MIR 2906 |
| TransIT-HeLaMONSTER Transfection Kit – 5 X 1.0 mL | MIR 2905 |
| TransIT-Insect Transfection Reagent – 0.4 mL | MIR 6104 |
| TransIT-Insect Transfection Reagent – 1.0 mL | MIR 6100 |
| TransIT-Insect Transfection Reagent – 10 X 1.0 mL | MIR 6106 |
| TransIT-Insect Transfection Reagent – 5 X 1.0 mL | MIR 6105 |
| TransIT-Jurkat Transfection Reagent – 0.4 mL | MIR 2124 |
| TransIT-Jurkat Transfection Reagent – 1.0 mL | MIR 2120 |
| TransIT-Jurkat Transfection Reagent – 10 X 1.0 mL | MIR 2126 |
| TransIT-Jurkat Transfection Reagent – 5 X 1.0 mL | MIR 2125 |
| TransIT-Keratinocyte Transfection Reagent – 0.4 mL | MIR 2804 |
| TransIT-Keratinocyte Transfection Reagent – 1.0 mL | MIR 2800 |
| TransIT-Keratinocyte Transfection Reagent – 10 X 1.0 mL | MIR 2806 |
| TransIT-Keratinocyte Transfection Reagent – 5 X 1.0 mL | MIR 2805 |
| TransIT-LT1 Transfection Reagent – 0.4 mL | MIR 2304 |
| TransIT-LT1 Transfection Reagent – 5 X 1.0 mL | MIR 2305 |
| TransIT-mRNA Transfection Kit – 0.4 mL | MIR 2225 |
| TransIT-mRNA Transfection Kit – 1.0 mL | MIR 2250 |
| TransIT-mRNA Transfection Kit – 10 X 1.0 mL | MIR 2256 |
| TransIT-mRNA Transfection Kit – 5 X 1.0 mL | MIR 2255 |
| TransIT-Oligo Transfection Reagent – 0.4 mL | MIR 2164 |
| TransIT-Oligo Transfection Reagent – 1.0 mL | MIR 2160 |
| TransIT-Oligo Transfection Reagent – 10 X 1.0 mL | MIR 2166 |
| TransIT-Oligo Transfection Reagent – 5 X 1.0 mL | MIR 2165 |
| TransIT-PRO Transfection Kit – 1.0 mL (with boost) | MIR 5700 |
| TransIT-PRO Transfection Kit – 10 mL (with boost) | MIR 5760 |
| TransIT-PRO Transfection Reagent – 1 mL (without boost) | MIR 5740 |
| TransIT-PRO Transfection Reagent – 10 mL (without boost) | MIR 5750 |
| TransIT-siQUEST Transfection Reagent – 0.4 mL | MIR 2114 |
| TransIT-siQUEST Transfection Reagent – 1.5 mL | MIR 2110 |
| TransIT-siQUEST Transfection Reagent – 10 X 1.5 mL | MIR 2116 |
| TransIT-siQUEST Transfection Reagent – 5 X 1.5 mL | MIR 2115 |
| TransIT-TKO Transfection Reagent – 0.4 mL | MIR 2154 |
| TransIT-TKO Transfection Reagent – 1.5 mL | MIR 2150 |
| TransIT-TKO Transfection Reagent – 10 X 1.5 mL | MIR 2156 |
| TransIT-TKO Transfection Reagent – 5 X 1.5 mL | MIR 2155 |
| TransIT-X2 Dynamic Delivery System – 0.3 mL | MIR 6003 |
| TransIT-X2 Dynamic Delivery System – 0.75 mL | MIR 6004 |
| TransIT-X2 Dynamic Delivery System – 1.5mL | MIR 6000 |
| TransIT-X2 Dynamic Delivery System – 10 X 1.5 mL | MIR 6006 |
| TransIT-X2 Dynamic Delivery System – 5 X 1.5 mL | MIR 6005 |
| Ingenio Electroporation Accessory – Cell Droppers (50 pk) | MIR 50125 |
| Ingenio Electroporation Solution Only – 25 rxns (6.25 mL) | MIR 50111 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 100 µg nucleic acid | MIR 3400 |
| Label IT Plasmid Delivery Control, Cy3 – 10 µg | MIR 7904 |
| Label IT RNAi Delivery Control, Cy3 – 10 µg (0.75 nmol) | MIR 7900 |
| TransduceIT Transduction Reagent – 1 mL | MIR 6620 |
| TransIT-BrCa Reagent Transfection Reagent – 0.4 mL | MIR 5504 |
| Ingenio Electroporation Accessory – 0.4 cm Cuvettes (50 pk) | MIR 50123 |
| Ingenio Electroporation Solution Only – 50 rxns (12.5 mL) | MIR 50114 |
| Label IT Nucleic Acid Labeling Kit, Biotin – labels 25 µg nucleic acid | MIR 3425 |
| Label IT Plasmid Delivery Control, Cy3 – 100 µg | MIR 7905 |
| Label IT RNAi Delivery Control, Cy3 – 100 µg (7.5 nmol) | MIR 7901 |
| Label IT siRNA Tracker Intracellular Localization Kit, CX-Rhodamine – labels 50 µg siRNA | MIR 7214 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, CX-Rhodamine – labels 50-200 µg plasmid DNA | MIR 7022 |
| Lentivirus Packaging Mix – 34 rxn | MIR 6640 |
| TransIT-BrCa Reagent Transfection Reagent – 1.0 mL | MIR 5500 |
| TransIT-LT1 Transfection Reagent – 1.0 mL | MIR 2300 |
| Ingenio Electroporation Accessory – 0.2 cm Cuvettes (50 pk) | MIR 50121 |
| Ingenio Electroporation Solution Only – 100 rxns (25 mL) | MIR 50117 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 100 µg nucleic acid | MIR 3100 |
| Label IT Plasmid Delivery Control, Fluorescein – 10 µg | MIR 7906 |
| Label IT RNAi Delivery Control, Fluorescein – 10 µg (0.75 nmol) | MIR 7902 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy3 – labels 50 µg siRNA | MIR 7212 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy3 – labels 50-200 µg plasmid DNA | MIR 7020 |
| Lentivirus Packaging Mix – 5 rxn | MIR 6630 |
| TransIT-BrCa Transfection Reagent – 5 x 1.0 mL | MIR 5505 |
| Ingenio Electroporation Kit, for Amaxa – 25 rxns (0.2 cm Cuvettes/Droppers) | MIR 50112 |
| Label IT Nucleic Acid Labeling Kit, CX-Rhodamine – labels 25 µg nucleic acid | MIR 3125 |
| Label IT Plasmid Delivery Control, Fluorescein – 100 µg | MIR 7907 |
| Label IT RNAi Delivery Control, Fluorescein – 100 µg (7.5 nmol) | MIR 7903 |
| Label IT siRNA Tracker Intracellular Localization Kit, Cy5 – labels 50 µg siRNA | MIR 7213 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Cy5 – labels 50-200 µg plasmid DNA | MIR 7021 |
| TransIT Lentivirus System – 34 rxn | MIR 6655 |
| TransIT-BrCa Transfection Reagent – 10 x 1.0 mL | MIR 5506 |
| TransIT-LT1 Transfection Reagent – 10 X 1.0 mL | MIR 2306 |
| Ingenio Electroporation Kit, for Amaxa – 50 rxns (0.2 cm Cuvettes/Droppers) | MIR 50115 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 100 µg nucleic acid | MIR 3600 |
| Label IT siRNA Tracker Intracellular Localization Kit, Fluorescein – labels 50 µg siRNA | MIR 7216 |
| Label IT Tracker Intracellular Nucleic Acid Localization Kit, Fluorescein – labels 50-200 µg plasmid DNA | MIR 7025 |
| TransIT Lentivirus System – 5 rxn | MIR 6650 |
| Ingenio Electroporation Kit, for Amaxa – 100 rxns (0.2 cm Cuvette/Droppers) | MIR 50118 |
| Label IT Nucleic Acid Labeling Kit, Cy3 – labels 25 µg nucleic acid | MIR 3625 |
| TransIT-Lenti Transfection Reagent – 10 x 1.5 mL | MIR 6606 |
| Ingenio Electroporation Kit, for other Electroporators – 25 rxns, (0.4 cm Cuvettes/Droppers) | MIR 50113 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 100 µg nucleic acid | MIR 3700 |
| TransIT-Lenti Transfection Reagent – 1.5 mL | MIR 6600 |
| Ingenio Electroporation Kit, for other Electroporators – 50 rxns (0.4 cm Cuvettes/Droppers) | MIR 50116 |
| Label IT Nucleic Acid Labeling Kit, Cy5 – labels 25 µg nucleic acid | MIR 3725 |
| TransIT-Lenti Transfection Reagent – 0.75 mL | MIR 6604 |
| Ingenio Electroporation Kit, for other Electroporators – 100 rxns (0.4 cm Cuvette/Droppers) | MIR 50119 |
| TransIT-Lenti Transfection Reagent – 5 x 1.5 mL | MIR 6605 |
| TransIT-Lenti Transfection Reagent – 0.3 mL | MIR 6603 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 100 µg nucleic acid | MIR 3800 |
| Label IT Nucleic Acid Labeling Kit, DNP – labels 25 µg nucleic acid | MIR 3825 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 100 µg nucleic acid | MIR 3200 |
| Label IT Nucleic Acid Labeling Kit, Fluorescein – labels 25 µg nucleic acid | MIR 3225 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 100 µg nucleic acid | MIR 7100 |
| Label IT Nucleic Acid Labeling Kit, MFP488 – labels 25 µg nucleic acid | MIR 7125 |
| TransIT-EE Delivery Solution – 40 Injections | MIR 5340 |
| TransIT-QR Delivery Solution – 40 Injections | MIR 5240 |
| pLIVE Vector – 20 ug | MIR 5420 |
| pLIVE Vector/LacZ – 20 ug of each vector | MIR 5520 |
| pLIVE Vector/SEAP Control Vector Kit – 20 ug of each vector | MIR 5620 |
| pLIVE Vector Complete System – 20 ug of each vector | MIR 5320 |
| RevIT AAV Enhancer – 1.5 mL (for 1 L of cell culture) | MIR 8000 |
| TransIT-VirusGEN GMP Transfection Reagent – 150 mL | MIR 6845-GMP |
| VirusGEN AAV Transfection Kit – 150mL | MIR 6755 |
| VirusGEN AAV Transfection Kit, 1 Kit – for 10 L of cell culture | MIR 6745 |
| RevIT AAV Enhancer – 10 x 1.5 mL (for 10 L of cell culture) | MIR 8006 |
| RevIT AAV Enhancer – 75 mL (for 50 L of cell culture) | MIR 8080 |
| VirusGEN GMP LV Transfection Kit | MIR 6825-GMP |
| VirusGEN LV Transfection Kit | MIR 6760 |
| VirusGEN AAV Kit + RevIT for 10L Culture | MIR 8008 |
| VirusGEN GMP AAV Transfection Kit | MIR 6815-GMP |
| VirusGEN AAV Transfection Kit – 1 Kit for 1 L of cell culture | MIR 6750 |
| VirusGEN AAV Kit + RevIT for 1L Culture | MIR 8007 |
| TransIT-VirusGEN Transfection Reagent – 150 mL | MIR 6740 |
| TransIT-VirusGEN Transfection Reagent – 30 mL | MIR 6720 |
| TransIT-VirusGEN Transfection Reagent – 10 x 1.5 mL | MIR 6706 |
| TransIT-VirusGEN Transfection Reagent – 5 x 1.5 mL | MIR 6705 |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

DRG是一家专业医疗诊断试剂、设备的制造商和经销商,并在100多个国家有分支机构和合作伙伴。DRG®公司重点发展高科技精准医疗诊断产品,涉及领域有:肿瘤、妇科、内分泌科、糖尿病、自体免疫、传染病和毒理学等。DRG®还拥有高水准的专业医疗、临床、营销策划和服务方面的专家,通过与分布在世界各地的分公司及代理商的合作,DRG®公司为全世界的客户提供全方位质优创新的临床检验产品和服务。
DRG International, Inc. is a leading specialty medical diagnostics and equipment manufacturer, and distributor with operations in more than 110 countries. Founded in 1970, DRG International provides a complete range of products and services to the diagnostics and cardiology-related medical community. DRG International’s global headquarters is conveniently situated in Springfield, New Jersey, accessible from State Route 22 and minutes away from route I-78 and the Garden State Parkway. Only 20 miles from New York City and 80 miles from Philadelphia, PA, DRG International, Inc. is in the heart of the beautiful Tri-State Area.
DRG international公司的主要产品包括:
Chemiluminescence Immunoassays (CLAS)
Diabetes / Gastrointestinal and Pankreatic
Drug Monitoring
Endocrinology
Fertility and Pregnancy
Pituitary / Adrenal Function
Immunology / Hematology
Cardiovascular Diseases
Bone and Mineral Metabolism
Leukotrienes and Prostaglandins
Neuropeptides
Thyroid Function
Saliva Diagnostics
Tumor Diagnosis
Infectious Diseases
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="DRG International"> DRG International
Trevigen致力于为研究人员提供高品质的试剂和试剂盒,用于细胞程序性死亡、DNA损伤和修复的研究。在过去的十年里,对于凋亡的研究越来越多,然而直到最近才开始将凋亡与DNA损伤联系在一起,并给予极大的关注。Trevigen能够为这一新兴领域提供高水平的产品和支持。而基于Trevigen在肿瘤研究产品核心业务的自然延伸,Trevigen开发出了一系列用于研究肿瘤细胞功能和行为的产品,包括血管生成、细胞侵袭、浸润和肿瘤形成等产品和试剂盒。所有Trevigen品牌的产品均基于最高质量标准生产,并被给予最强有力的技术支持。
Trevigen, Inc. is an innovative biotechnology company focused on the development of products and technology for cancer research and genetic toxicology, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 “Technology Corridor” in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://norgen.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Trevigen"> Trevigen地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18372041646
邮箱:sales@amyjet.com
0.3635